Therapeutic Outcome in Invasive Aspergillosis
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
A review of series of > or = 4 cases of invasive aspergillosis (total, 1,223 cases) was undertaken to establish the crude mortality and rate of response to therapy with amphotericin B in the major at-risk host groups. In association with pulmonary, sinus, and cerebral aspergillosis in immunocompromised patients, the crude mortality rates were 86%, 66%, and 99%, respectively. No untreated patient survived. Among 84 patients treated for 1-13 days, only one survived. Among those with invasive pulmonary aspergillosis treated for > or = 14 days, the response rates to amphotericin B deoxycholate were 83% (in cases of heart and renal transplantation), 54% (leukemia), 33% (bone marrow transplantation) and 20% (liver transplantation). Patients with AIDS mostly received both amphotericin B and itraconazole, and 37% of those treated for > or = 14 days responded to therapy. Substantial variation in outcome from series to series was related to underlying disease status, site of disease, and management. Invasive aspergillosis remains a devastating opportunistic infection despite current treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases
Denning, D. W., & Stevens, D. A. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.6.1147 · Cited by 899
Self-citationFungal infections in cancer patients: An international autopsy survey
Bodey, G., Bueltmann, B., Duguid, W., Gibbs, D., Hanak, H., Hotchi, M., Mall, G., Martino, P., Meunier, F., Milliken, S., et al. (1992) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01967060 · Cited by 547
Pulmonary Aspergillosis in the Acquired Immunodeficiency Syndrome
Denning, D. W., Follansbee, S. E., Scolaro, M., Norris, S., Edelstein, H., & Stevens, D. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103073241003 · Cited by 503
Self-citationNIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
Denning, D. W., Lee, J. Y., Hostetler, J. S., Pappas, P., Kauffman, C. A., Dewsnup, D. H., Galgiani, J. N., Graybill, J. R., Sugar, A. M., Catanzaro, A., et al. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90023-x · Cited by 450
Self-citationKuhlman, J. E., Fishman, E. K., & Siegelman, S. S. (1985) · Radiology · doi:10.1148/radiology.157.3.3864189 · Cited by 448
Treatment of Invasive Aspergillosis: Relation of Early Diagnosis and Treatment to Response
AISNER, J., SCHIMPFF, S. C., & WIERNIK, P. H. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-86-5-539 · Cited by 397
Chronic Necrotizing Pulmonary Aspergillosis: A Discrete Clinical Entity
BINDER, R. E., FALING, L. J., PUGATCH, R. D., MAHASAEN, C., & SNIDER, G. L. (1982) · Medicine · doi:10.1097/00005792-198203000-00005 · Cited by 391
Fungal infections in patients with acute leukemia
Degregorio, M. W., Lee, W. M. F., Linker, C. A., Jacobs, R. A., & A. Ries, C. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90334-5 · Cited by 354
Impact of air filtration on nosocomial aspergillus infections
Sherertz, R. J., Belani, A., Kramer, B. S., Elfenbein, G. J., Weiner, R. S., Sullivan, M. L., Thomas, R. G., & Samsa, G. P. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90902-8 · Cited by 333
FUNGAL INFECTIONS IN LIVER TRANSPLANT RECIPIENTS
WAJSZCZUK, C. P., DUMMER, J. S., HO, M., VAN THIEL, D. H., STARZL, T. E., IWATSUKI, S., & SHAW, B. (1985) · Transplantation · doi:10.1097/00007890-198510000-00002 · Cited by 271
Cited by
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307
“The overall success rate of AmB therapy for IA is 34% (141, 221, 533).”
BackgroundInfluentialAspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Self-citationInvasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Practice Guidelines for Diseases Caused by Aspergillus
Stevens, D. A., Kan, V. L., Judson, M. A., Morrison, V. A., Dummer, S., Denning, D. W., Bennett, J. E., Walsh, T. J., Patterson, T. F., & Pankey, G. A. (2000) · Clinical Infectious Diseases · doi:10.1086/313756 · Cited by 789
Self-citationTrends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
A Clinical Algorithm to Diagnose Invasive Pulmonary Aspergillosis in Critically Ill Patients
Blot, S. I., Taccone, F. S., Van den Abeele, A.-M., Bulpa, P., Meersseman, W., Brusselaers, N., Dimopoulos, G., Paiva, J. A., Misset, B., Rello, J., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201111-1978oc · Cited by 628
The Clinical Spectrum of Pulmonary Aspergillosis
Soubani, A. O., & Chandrasekar, P. H. (2002) · Chest · doi:10.1378/chest.121.6.1988 · Cited by 594
Verweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561
“99% [56] Review of 141 cases of CNS IA in immunocompromised patients, of whom 140 died.”
BackgroundChanging epidemiology of systemic fungal infections
Richardson, M., & Lass-Flörl, C. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01978.x · Cited by 524
“Data compiled from references [6,9,20,110,111,113,114, 119–124].”
Maertens, J., Verhaegen, J., Lagrou, K., Van Eldere, J., & Boogaerts, M. (2001) · Blood · doi:10.1182/blood.v97.6.1604 · Cited by 513
Fukuda, T., Boeckh, M., Carter, R. A., Sandmaier, B. M., Maris, M. B., Maloney, D. G., Martin, P. J., Storb, R. F., & Marr, K. A. (2003) · Blood · doi:10.1182/blood-2003-02-0456 · Cited by 465
Improved outcome in central nervous system aspergillosis, using voriconazole treatment
Schwartz, S. (2005) · Blood · doi:10.1182/blood-2005-02-0733 · Cited by 391
Maertens, J., Verhaegen, J., Demuynck, H., Brock, P., Verhoef, G., Vandenberghe, P., Van Eldere, J., Verbist, L., & Boogaerts, M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.10.3223-3228.1999 · Cited by 376
Identification of Aspergillus Species Using Internal Transcribed Spacer Regions 1 and 2
Henry, T., Iwen, P. C., & Hinrichs, S. H. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.4.1510-1515.2000 · Cited by 372
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Invasive aspergillosis in the intensive care unit
Meersseman, W., Lagrou, K., Maertens, J., & Wijngaerden, E. V. (2007) · Clinical Infectious Diseases · doi:10.1086/518852 · Cited by 366
Cornillet, A., Camus, C., Nimubona, S., Gandemer, V., Tattevin, P., Belleguic, C., Chevrier, S., Meunier, C., Lebert, C., Aupee, M., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/505870 · Cited by 361
Molecular architecture of fungal cell walls revealed by solid-state NMR
Kang, X., Kirui, A., Muszyński, A., Widanage, M. C. D., Chen, A., Azadi, P., Wang, P., Mentink-Vigier, F., & Wang, T. (2018) · Nature Communications · doi:10.1038/s41467-018-05199-0 · Cited by 356
Maertens, J., Van Eldere, J., Verhaegen, J., Verbeken, E., Verschakelen, J., & Boogaerts, M. (2002) · The Journal of Infectious Diseases · doi:10.1086/343804 · Cited by 343
Bowden, R., Chandrasekar, P., White, M. H., Li, X., Pietrelli, L., Gurwith, M., van Burik, J., Laverdiere, M., Safrin, S., & Wingard, J. R. (2002) · Clinical Infectious Diseases · doi:10.1086/341401 · Cited by 335
Tsai, H.-F., Chang, Y. C., Washburn, R. G., Wheeler, M. H., & Kwon-Chung, K. J. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.12.3031-3038.1998 · Cited by 334
Current Approaches to Diagnosis and Treatment of Invasive Aspergillosis
Segal, B. H., & Walsh, T. J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200505-727so · Cited by 334
Paulussen, C., Hallsworth, J. E., Álvarez‐Pérez, S., Nierman, W. C., Hamill, P. G., Blain, D., Rediers, H., & Lievens, B. (2017) · Microbial Biotechnology · doi:10.1111/1751-7915.12367 · Cited by 334
Invasive Aspergillosis in 2002: An Update
Kontoyiannis, D., & Bodey, G. (2002) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/s10096-002-0699-z · Cited by 326
Leenders, A. C. A. P., Daenen, S., Jansen, R. L. H., Hop, W. C. J., Lowenberg, B., Wijermans, P. W., Cornelissen, J., Herbrecht, R., Lelie, H. V. D., Hoogsteden, H. C., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00944.x · Cited by 319
Risk Factors for Invasive Aspergillosis in Solid-Organ Transplant Recipients: A Case-Control Study
Gavalda, J., Len, O., San Juan, R., Aguado, J. M., Fortun, J., Lumbreras, C., Moreno, A., Munoz, P., Blanes, M., Ramos, A., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/430602 · Cited by 317
“lated mortality is still 170% for SOT recipients [3, 4].”
BackgroundAmphotericin B Formulations and Drug Targeting
Torrado, J. J., Espada, R., Ballesteros, M. P., & Torrado-Santiago, S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21179 · Cited by 299
Denning, D. W., Marr, K. A., Lau, W. M., Facklam, D. P., Ratanatharathorn, V., Becker, C., Ullmann, A. J., Seibel, N. L., Flynn, P. M., van Burik, J.-A. H., et al. (2006) · Journal of Infection · doi:10.1016/j.jinf.2006.03.003 · Cited by 294
Self-citationAspergillus fumigatus cell wall: composition and biosynthesis
Bernard, M., & Latgé, J.-P. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.9.17 · Cited by 282
Kawazu, M., Kanda, Y., Nannya, Y., Aoki, K., Kurokawa, M., Chiba, S., Motokura, T., Hirai, H., & Ogawa, S. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2733-2741.2004 · Cited by 280
Ullmann, A. J., Cornely, O. A., Burchardt, A., Hachem, R., Kontoyiannis, D. P., Töpelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.658-666.2006 · Cited by 273
Denning, D. W., Marinus, A., Cohen, J., Spence, D., Herbrecht, R., Pagano, L., Kibbler, C., Kermery, V., Offner, F., Cordonnier, C., et al. (1998) · Journal of Infection · doi:10.1016/s0163-4453(98)80173-4 · Cited by 256
Self-citationRole of TNF-α in Pulmonary Host Defense in Murine Invasive Aspergillosis
Mehrad, B., Strieter, R. M., & Standiford, T. J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1633 · Cited by 240
Balloy, V., Huerre, M., Latgé, J.-P., & Chignard, M. (2005) · Infection and Immunity · doi:10.1128/iai.73.1.494-503.2005 · Cited by 231
Espinel-Ingroff, A., Fothergill, A., Peter, J., Rinaldi, M. G., & Walsh, T. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.9.3204-3208.2002 · Cited by 203
“terreus 2 MFC 2– 8 (4) 2– 8 (4) 2 MIC 0.”
BackgroundInfluentialSlaven, J. W., Anderson, M. J., Sanglard, D., Dixon, G. K., Bille, J., Roberts, I. S., & Denning, D. W. (2002) · Fungal Genetics and Biology · doi:10.1016/s1087-1845(02)00016-6 · Cited by 202
Self-citationReviews Of Anti‐infective Agents: Anidulafungin: A Novel Echinocandin
Vazquez, J. A., & Sobel, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/505204 · Cited by 199
Caillot, D., Thiébaut, A., Herbrecht, R., de Botton, S., Pigneux, A., Bernard, F., Larché, J., Monchecourt, F., Alfandari, S., & Mahi, L. (2007) · Cancer · doi:10.1002/cncr.23109 · Cited by 190
“I nvasive aspergillosis (IA) is a major complication with a high mortality rate in immunocompromised patients.(1) For decades, the recommended treatment for IA has been amphotericin B (AmB) deoxycholate.”
BackgroundWasylnka, J. A., & Moore, M. M. (2002) · Infection and Immunity · doi:10.1128/iai.70.6.3156-3163.2002 · Cited by 188
“Early diagnosis of invasive aspergillosis is crucial (12), and even with treatment, the mortality rate exceeds 65% (11).”
BackgroundUtility of Aspergillus Antigen Detection in Specimens Other than Serum Specimens
Klont, R. R., Mennink-Kersten, M. A. S. H., & Verweij, P. E. (2004) · Clinical Infectious Diseases · doi:10.1086/425317 · Cited by 182
“00 initiation of therapy improves outcome [5, 7, 8].”
Aspergillus fumigatus conidia survive and germinate in acidic organelles of A549 epithelial cells
Wasylnka, J. A., & Moore, M. M. (2003) · Journal of Cell Science · doi:10.1242/jcs.00329 · Cited by 161
Review of Newer Antifungal and Immunomodulatory Strategies for Invasive Aspergillosis
Steinbach, W. J., & Stevens, D. A. (2003) · Clinical Infectious Diseases · doi:10.1086/376523 · Cited by 161
“Unfortunately, amphotericin B is at best only moderately effective against IA [4], and therapy may be ineffective in the absence of bone marrow recovery.”
BackgroundBurden of aspergillosis-related hospitalizations in the United States
Dasbach, E. J., Davies, G. M., & Teutsch, S. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317487 · Cited by 159
Wildfeuer, A., Seidl, H. P., Paule, I., & Haberreiter, A. (1998) · Mycoses · doi:10.1111/j.1439-0507.1998.tb00344.x · Cited by 140
Chiou, C. C., Mavrogiorgos, N., Tillem, E., Hector, R., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3310-3321.2001 · Cited by 117
“Furthermore, the overall efficacy of either drug is limited, as evidenced by the high mortality associated with aspergillosis and other filamentous fungal infections (2).”
BackgroundNucci, M., Nouér, S. A., Grazziutti, M., Kumar, N. S., Barlogie, B., & Anaissie, E. (2010) · Clinical Infectious Diseases · doi:10.1086/657065 · Cited by 112
Anidulafungin: A new echinocandin with a novel profile
Vazquez, J. A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.010 · Cited by 78
Reeves, E. P., Reiber, K., Neville, C., Scheibner, O., Kavanagh, K., & Doyle, S. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05315.x · Cited by 70
Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology
Lass-Flörl, C., Cuenca-Estrella, M., Denning, D. W., & Rodriguez-Tudela, J. L. (2006) · Medical Mycology · doi:10.1080/13693780600779401 · Cited by 69
“The use of MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] or XTT (2,3-bis (2methoxy-4-nitro-5-dulfophenyl)-5-[(phenylamino)car bonyl]-2H-tetrazoliumhydroxide)asacolorimetric markerforredoxpotentialhasbeenfoundconvenient for Aspergillus [33,34].”
BackgroundMethodSelf-citationParkes‐Ratanshi, R., Achan, B., Kwizera, R., Kambugu, A., Meya, D., & Denning, D. W. (2015) · Mycoses · doi:10.1111/myc.12387 · Cited by 49
Self-citationAspergillus fumigatus and Aspergillosis
(2008) · doi:10.1128/9781555815523 · Cited by 31
Seltene Erkrankungen der Orbita
Kisser, U., Heichel, J., & Glien, A. (2021) · Laryngo-Rhino-Otologie · doi:10.1055/a-1384-4641 · Cited by 20
Metadata
- Authors
- Denning, D. W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-09-01
- Volume
- 23
- Issue
- 3
- Pages
- 608-615
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2160143310
- Cited by
- 689
- References
- 78
- FWCI
- 24.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.